Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Cytokinetics Inc., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×
Dec 31, 2019 = ×
Dec 31, 2018 = ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Return on Assets (ROA)
The ROA exhibits significant negative values throughout the five-year period, indicating persistent inefficiency in generating profit from assets. Initially, it was extremely negative at -50.33% in 2018, slightly improving to -41.99% in 2019. A marked improvement is observed in 2020, with ROA reaching -23.85%, but this improvement was not sustained as the metric deteriorated again to -25.59% in 2021 and further declined to -38.33% in 2022. The overall trend suggests continued operational challenges and declining asset utilization efficiency after a temporary improvement in 2020.
Financial Leverage
Financial Leverage data is partially available for 2018, 2020, and 2021. In 2018, it was notably high at 8.14, indicating a heavy reliance on debt relative to equity. This measure improved over the years where data is present, declining significantly to 4.71 in 2020 and further decreasing to 3.45 in 2021. This reduction in leverage could imply a strategic effort to reduce debt levels or increase equity financing, potentially aimed at lowering financial risk. Data for 2019 and 2022 are missing, so the complete trend cannot be fully assessed.
Return on Equity (ROE)
ROE shows extremely negative values for all years where data is available, signaling that the company generated substantial losses relative to shareholders' equity. In 2018, the ROE was exceptionally low at -409.84%, indicating severe capital inefficiency or accounting losses. Though data for 2019 is unavailable, there is a significant improvement observed in 2020 with ROE at -112.27%, further improving to -88.29% in 2021. Despite this improvement, the ROE remains deeply negative, underscoring ongoing challenges in providing returns to equity holders.

Three-Component Disaggregation of ROE

Cytokinetics Inc., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×
Dec 31, 2019 = × ×
Dec 31, 2018 = × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial data reveals several notable trends in profitability, asset utilization, and leverage over the five-year period examined.

Net Profit Margin
The net profit margin remained deeply negative throughout the period, indicating ongoing losses. After a sharp decline from -337.41% in 2018 to -452.93% in 2019, the margin improved significantly in 2020 to -228%, suggesting a reduction in the scale of losses. However, this improvement was temporary, as profit margins worsened again in 2021 and 2022, finishing at -305.72% and -411.21%, respectively. This pattern signifies persistent unprofitability with fluctuations in loss severity.
Asset Turnover
Asset turnover ratios remained low over the period, fluctuating between 0.08 and 0.15. The highest ratio was observed in 2018 at 0.15, followed by a decline to 0.09 in 2019 and minimal variation thereafter. This indicates relatively inefficient use of assets to generate revenue, with no clear trend of improvement or deterioration.
Financial Leverage
Financial leverage showed a decreasing trend where data is available, starting at a high ratio of 8.14 in 2018, dropping to 4.71 in 2020, then further to 3.45 in 2021. Data for 2019 and 2022 were not reported. The decline suggests a reduction in reliance on debt or other liabilities relative to equity during the years reported, potentially indicating a strategy to reduce financial risk.
Return on Equity (ROE)
ROE was significantly negative in the years with available data, with a severe loss reported in 2018 at -409.84%. A marked improvement occurred by 2020 when ROE rose to -112.27%, and further to -88.29% in 2021, indicating a diminishing magnitude of losses relative to shareholder equity. The lack of data for 2019 and 2022 limits comprehensive analysis, but the available figures align with the observed net profit margin trend of reducing losses.

Overall, the financial metrics illustrate a company experiencing substantial and persistent losses, with slight improvements in profit margins and return on equity around 2020 and 2021. Asset utilization remains consistently low, while financial leverage appears to decrease, potentially reflecting efforts to manage financial risk amid challenging profitability conditions.


Five-Component Disaggregation of ROE

Cytokinetics Inc., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Dec 31, 2020 = × × × ×
Dec 31, 2019 = × × × ×
Dec 31, 2018 = × × × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


EBIT Margin
The EBIT margin has consistently remained negative throughout the analyzed period, indicating persistent operating losses. The margin was at its lowest in 2019 with -428.28%, then improved in 2020 to -199.41%, though it worsened again in 2021 to -282.38%, and further declined in 2022 to -390.68%. This fluctuation suggests volatility in operating efficiency and profitability, with no sustained recovery observed.
Asset Turnover
Asset turnover ratios were relatively low over the five-year span, ranging between 0.08 and 0.15. The highest ratio was recorded in 2018 at 0.15, followed by a decline to 0.09 in 2019 and a slight recovery to 0.10 in 2020. The ratio decreased again in 2021 to 0.08 and modestly increased to 0.09 in 2022. These values indicate limited efficiency in utilizing assets to generate sales, with no clear upward trend.
Financial Leverage
Financial leverage showed a declining trend from 8.14 in 2018 to 3.45 in 2021, with a missing value for 2019 and 2022. This suggests a reduction in reliance on debt or increased equity financing over time, potentially decreasing financial risk. However, gaps in the data limit a full understanding of recent leverage positions.
Return on Equity (ROE)
ROE values were significantly negative for the available years, with -409.84% in 2018, improving to -112.27% in 2020 and further to -88.29% in 2021. The absence of data for 2019 and 2022 restricts complete trend analysis. Despite the negative figures, the improving ROE suggests a reduction in net loss relative to shareholder equity over the observed period.
Tax Burden and Interest Burden
No data was provided for these metrics, limiting the ability to assess the impacts of taxation and interest expenses on profitability and earnings.

Two-Component Disaggregation of ROA

Cytokinetics Inc., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×
Dec 31, 2019 = ×
Dec 31, 2018 = ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The financial data reveals several notable trends over the analyzed five-year period.

Net Profit Margin
The net profit margin has consistently remained negative, indicating that the company has not achieved profitability in these years. The margin showed significant fluctuations, with a peak negative value of -452.93% in 2019, which improved substantially to -228% in 2020, suggesting a temporary reduction in losses. However, the margin deteriorated again in 2021 to -305.72% and further declined to -411.21% in 2022, signaling increasing losses toward the end of the period.
Asset Turnover
Asset turnover has been relatively low throughout the period, reflecting limited efficiency in generating revenues from assets. It started at 0.15 in 2018, then decreased sharply to 0.09 in 2019. It slightly improved to 0.10 in 2020 but decreased again to 0.08 in 2021, followed by a small recovery to 0.09 in 2022. These fluctuations imply ongoing challenges in optimizing asset utilization.
Return on Assets (ROA)
Similar to the net profit margin, the return on assets remained negative during all years analyzed, indicating losses relative to the asset base. The ROA improved from -50.33% in 2018 to -23.85% in 2020, suggesting some operational improvements. However, it worsened again in subsequent years, reaching -38.33% in 2022. This pattern highlights persisting difficulties in generating returns from the company's assets.

Overall, the company's financial performance exhibited continued losses with volatile margins and limited efficiency in asset utilization. The temporary improvements observed around 2020 were not sustained, and the declining profitability and ROA in the later years point to ongoing operational and financial challenges.


Four-Component Disaggregation of ROA

Cytokinetics Inc., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Dec 31, 2020 = × × ×
Dec 31, 2019 = × × ×
Dec 31, 2018 = × × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


EBIT Margin
The EBIT margin demonstrates a consistently negative trend throughout the analyzed period. Starting at -325.36% in 2018, it deteriorated further to -428.28% in 2019, which represents the lowest point. There was a partial recovery in 2020 to -199.41%, followed by a decline again in 2021 to -282.38%, and further worsening in 2022 to -390.68%. This pattern indicates persistent operational losses and volatility in earnings before interest and taxes, with no sustained improvement during these years.
Asset Turnover
The asset turnover ratio remains relatively low and stable, fluctuating slightly between 0.08 and 0.15. It started at 0.15 in 2018, decreased to 0.09 in 2019, experienced a minor increase to 0.10 in 2020, declined again to 0.08 in 2021, and returned to 0.09 in 2022. These figures suggest limited efficiency in generating revenue from assets, with marginal variation but no significant upward or downward trend.
Return on Assets (ROA)
Return on assets exhibits a negative but improving trend from 2018 through 2020, moving from -50.33% to -23.85%. However, this trend reverses after 2020, with ROA worsening to -25.59% in 2021 and further declining to -38.33% in 2022. Overall, the return on assets remains negative throughout the period, indicating a continuous inability to generate positive returns from the asset base despite some improvement early on.
Tax Burden and Interest Burden
No data was available for the tax burden and interest burden ratios over the reviewed periods, preventing any analysis of their impact on overall profitability and financial structure.
Summary
The financial performance metrics reveal ongoing challenges in profitability, operational efficiency, and asset utilization. The highly negative EBIT margin and ROA indicate that the company consistently operated at a loss and struggled with effective asset deployment. The stable but low asset turnover further corroborates limited revenue generation capacity from its assets. The lack of data for tax and interest burden metrics limits the ability to fully understand the effects of financial leverage and taxation on these outcomes. Overall, the trends reflect a period of financial difficulty without sustained recovery up to the end of 2022.

Disaggregation of Net Profit Margin

Cytokinetics Inc., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×
Dec 31, 2019 = × ×
Dec 31, 2018 = × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


EBIT Margin
The EBIT Margin has consistently been negative throughout the observed period from 2018 to 2022. The margin was at its lowest in 2019 with a value of -428.28%, indicating significant operating losses. Although there was some improvement in 2020, reaching -199.41%, the margin again deteriorated in subsequent years, showing -282.38% in 2021 and a further decline to -390.68% in 2022. This suggests fluctuating but persistently negative operating profitability, with no sustained recovery.
Net Profit Margin
Similar to the EBIT Margin, the Net Profit Margin remained negative over the entire period, reflecting ongoing net losses. The margin reached its most severe point in 2019 at -452.93%, indicating substantial negative returns. While there was some improvement in 2020 to -228.00%, the margin worsened again in 2021 to -305.72%, and further declined to -411.21% in 2022. This trend underscores consistent net losses with considerable volatility but no clear move toward profitability.
Tax Burden and Interest Burden
There is no data available for Tax Burden and Interest Burden for any year in the given period, which limits the capacity to analyze the impact of taxes and interest expenses on the company's profitability and financial structure.
Overall Financial Performance
The company's financial performance as depicted by margins is characterized by persistent and deep operating and net losses. The volatility in margins suggests fluctuations in costs or revenues, but no sustained improvement or trend toward profitability is evident. The absence of data for tax and interest burdens restricts more detailed analysis of factors influencing net profit beyond operating results.